FLT3 mutation is a highly relevant target given its specificity and role in the biology of AML. There are a number of small-molecule receptor tyrosine kinase inhibitors that target FLT3 ...
The collaboration has two specific objectives. The first objective is to study Actimab-A in combination with targeted therapies including FLT3 and menin inhibitors to define transcriptional profiles ...
Acquired global rights to GB3226, a novel dual ENL-YEATS and FLT3 inhibitor aimed at multiple genetic subsets of acute myeloid leukemia (AML), signaling a strategic focus on oncology. GB3226 is on ...
FLT3 mutation is a highly relevant target given its specificity and role in the biology of AML. There are a number of small-molecule receptor tyrosine kinase inhibitors that target FLT3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback